SLG
AXSM icon

Stanley-Laman Group’s Axsome Therapeutics AXSM Stock Holding History

Stanley-Laman Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.69M Sell
19,170
-90
-0.5% -$19.5K 0.48% 60
2026
Q1 		$3.26M Buy
19,260
+1,342
+7% +$232K 0.4% 102
2025
Q4 		$3.27M Buy
17,918
+417
+2% +$58.2K 0.42% 93
2025
Q3 		$2.13M Buy
+17,501
New +$1.97M 0.3% 121

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stanley-Laman Group's AXSM Position: Q2 2026 in Review

Stanley-Laman Group reduced its Axsome Therapeutics (AXSM) stake by 0.47% in Q2 2026, selling an estimated $19.5K and leaving 19,170 shares worth $4.69M. The position accounts for 0.48% of the portfolio, ranked #60.

Stanley-Laman Group first reported a position in AXSM in Q3 2025 and has held it in 4 quarters since. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Stanley-Laman Group held 19,170 shares of Axsome Therapeutics worth $4.69M as of Q2 2026.
  • Stanley-Laman Group sold 90 Axsome Therapeutics shares in Q2 2026, an estimated $19.5K.
  • Axsome Therapeutics made up 0.48% of Stanley-Laman Group's portfolio in Q2 2026, its #60 holding.
  • Stanley-Laman Group first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Stanley-Laman Group's 13F filing for Q2 2026, filed 5 Aug 2026.